Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
opioid |
| gptkbp:approvedBy |
1979
|
| gptkbp:ATCCode |
N02AF02
|
| gptkbp:brand |
gptkb:Nubain
|
| gptkbp:CASNumber |
20594-83-6
|
| gptkbp:contraindication |
respiratory depression
hypersensitivity to nalbuphine |
| gptkbp:controlledSubstanceSchedule |
No (US)
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:drugClass |
opioid
|
| gptkbp:eliminationHalfLife |
5 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C21H27NO4
|
| https://www.w3.org/2000/01/rdf-schema#label |
nalbuphine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
mu-opioid receptor antagonist
kappa-opioid receptor agonist |
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
50%
|
| gptkbp:routeOfAdministration |
intramuscular
subcutaneous intravenous |
| gptkbp:sideEffect |
nausea
vomiting dizziness sweating drowsiness dry mouth |
| gptkbp:UNII |
N7D6J3B44D
|
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:Thebaine
|
| gptkbp:bfsLayer |
6
|